Abstract 548P
Background
Lung cancer is the malignant tumor with the highest incidence rate and mortality in the world. The main types of lung cancer are nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC). With targeted therapy and immunotherapy emerging, treating NSCLC has made a great progress. However, the molecular mechanisms underlying progression of NSCLC remain elusive.
Methods
Completing gain- and loss-of-function experiments to view whether B-Myb regulates the function of lung cancer cells by targeting IGFBP3 in lung cancer cell lines H1299 and A549, respectively. Mechanistically, Using a stable strain of B-Myb lung cancer to build the animal model and collecting mouse blood to lymphocyte subgroup analysis by flow cytometry. Analyzing metabolic products of lung cancer by metabolomics.
Results
B-Myb increased in lung cancer tissues and cells notably, its expression interrelated with clinical stage and poor prognosis of patients with NSCLC. B-Myb may affect the proliferation, invasion, and migration of NSCLC by regulating IGFBP3. Importantly, overexpressing of B-Myb in NSCLC affects the expression of immune checkpoint PD-1/PD-L1 and lung cancer cell metabolism.
Conclusions
Our findings reveal that B-Myb may interact with IGFBP3 to promote the occurrence and development of NSCLC and affect immune checkpoints PD-1/PD-L1 expressing. B-Myb may become a potential new target for the diagnosis and treatment of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chongqing Municipal Education Commission.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract